
CLAIMS:

1. Use of a compound represented by Formula IA, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting tumor cell migration and establishment of metastasis in a subject suffering from cancer:



Formula IA

wherein

R_2 and R_3 are independently selected from H, OH, F or Cl;

X_1 is $(CH_2)_n$, wherein n is 0, 1 or 2; and




R_4 is $(CH_2)_{m1}$, $(CH_2)_{q1}CH=CH$, or $CH=CH(CH_2)$ wherein m1 is 4, 5 or 6 and q1 is 2, or 3.










2. The use of claim 1, wherein the pharmaceutically acceptable salt is a base addition salt.

3. The use of claim 2, wherein the base addition salt comprises a metal counterion, said metal counterion is sodium, potassium, magnesium, calcium or lithium.

4. The use of claim 3, wherein the metal counterion is sodium.

5. The use of claim 1, wherein the compound is any one of the following compounds:

	Structure
Compound I	
Compound II	
Compound III	

	Structure
Compound IV	
Compound V	
Compound VI	
Compound VII	
Compound VIII	
Compound IX	
Compound X	
Compound XIII	
Compound XXXVII	

6. The use of claim 5, wherein the compound is Compound I, II, VIII, or XIII.

7. The use of claim 5, wherein the compound is Compound I, or II.

8. The use of any one of claims 1 to 7, wherein the compound is to be administered with an anticancer agent.

9. The use of claim 8, wherein said anticancer agent is decarbazine, doxorubicin, daunorubicin, cyclophosphamide, busulfex, busulfan, vinblastine, vincristine, bleomycin, etoposide, topotecan, irinotecan, taxotere, taxol, 5-fluorouracil, methotrexate, gemcitabine, cisplatin, carboplatin or chlorambucil.

10. The use of any one of claims 1 to 7, wherein the cancer is bladder cancer, breast cancer, colorectal cancer, kidney cancer, melanoma, non-Hodgkin's lymphoma, leukemia, ovarian cancer, pancreatic cancer, prostate cancer or uterine cancer, and the subject is a human patient.

11. The use of claim 10, wherein the compound is to be administered with an anticancer agent.

12. The use of claim 11, wherein said anticancer agent is decarbazine, doxorubicin, daunorubicin, cyclophosphamide, busulfex, busulfan, vinblastine, vincristine, bleomycin, etoposide, topotecan, irinotecan, taxotere, taxol, 5-fluorouracil, methotrexate, gemcitabine, cisplatin, carboplatin or chlorambucil.

13. A pharmaceutical composition comprising a compound represented by Formula IA, as defined in claim 1 or a pharmaceutically acceptable salt thereof, or a compound as defined in claim 5, and a pharmaceutically acceptable carrier, for use in inhibiting tumor cell migration and establishment of metastasis in a subject suffering from cancer.

14. The pharmaceutical composition according to claim 13, wherein said composition further comprises an anticancer agent.

15. The pharmaceutical composition according to claim 14, wherein said anticancer agent is decarbazine, doxorubicin, daunorubicin, cyclophosphamide, busulfex, busulfan, vinblastine, vincristine, bleomycin, etoposide, topotecan, irinotecan, taxotere, taxol, 5-fluorouracil, methotrexate, gemcitabine, cisplatin, carboplatin and chlorambucil.

16. The pharmaceutical composition of any one of claims 13 to 15, wherein the cancer is bladder cancer, breast cancer, colorectal cancer, kidney cancer, melanoma, non-Hodgkin's lymphoma, leukemia, ovarian cancer, pancreatic cancer, prostate cancer or uterine cancer, and the subject is a human patient.